Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-22

Clinical Trial Update: Evaluation of Votrient in Angiosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Votrient (pazopanib) in angiosarcoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Votrient (Pazopanib)

Snippet

Sponsor: Heidelberg University | Conditions: Angiosarcoma | Phase 2 | Status: TERMINATED | Results posted: 2022-03-22